Selected Grants
Tri-Institutional Molecular Mycology and Pathogenesis Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029Development, Clinical Validation, and Readiness for Implementation of a Novel Mp1p D4 Point of Care Test for Rapid Diagnosis of Talaromycosis
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2028Tropical Medicine Research Center for Talaromycosis in Vietnam - U01
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2027Gilead Investigator Initiated Study
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2020 - 2025Interdisciplinary Research Training Program in AIDS
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2010 - 2025Tri-Institutional Molecular Mycology and Pathogenesis Training Program
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2024 - 2029Development, Clinical Validation, and Readiness for Implementation of a Novel Mp1p D4 Point of Care Test for Rapid Diagnosis of Talaromycosis
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2023 - 2028Tropical Medicine Research Center for Talaromycosis in Vietnam - U01
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2027Gilead Investigator Initiated Study
Clinical TrialPrincipal Investigator · Awarded by Gilead Sciences, Inc. · 2020 - 2025Interdisciplinary Research Training Program in AIDS
Inst. Training Prgm or CMEMentor · Awarded by National Institutes of Health · 2010 - 2025Development of a point of care lateral flow antigen test for talaromycosis
ResearchPrincipal Investigator · Awarded by IMMY · 2023 - 2025Making an early diagnosis of talaromycosis - an approach to reduce morbidity and mortality in advanced HIV infection in Southeast Asia
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2019 - 2025Mapping of the IgM and IgG antibody responses to Talaromyces marneffei infection in mice and humans - Deciphering acute from reactivated or latent infections (R21)
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2023Implications of mycoviral infection in Talaromyces marneffei: an analysis of human patient samples, RNAi, and hypermutation
ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2021 - 2023REPRODUCIBILITY AND CLINICAL SIGNIFICANCE OF THE CRAG SQ SCORES IN A COHORT ASYMPTOMATIC CRAG POSITIVE PATIENTS WITH ADVANCED HIV DISEASE IN VIETNAM - IIS
ResearchPrincipal Investigator · Awarded by CDC Foundation · 2023 - 2023Development of a Rapid Point of Care Diagnostic for the Detection of Talaromyces marneffei
ResearchPrincipal Investigator · Awarded by IMMY · 2021 - 2021Fellowships, Gifts, and Supported Research
Joint Global Health Trials Award. "A trial of itraconazole versus amphotericin B for initial therapy of HIV-associated penicilliosis" ·
2011
- 2017
PI ·
The Medical Research Council, the Wellcome Trust, and the Department of International Development in the UK
· $2,500,000.00
A randomized controlled trial of itraconazole versus amphotericin B for treatment of HIV-associated talaromycosis (penicilliosis)
Investigator Initiated Clinical Trials Award. "Randomized controlled trial of efficacy and hepatic safety of raltegravir-based and efavirenz-based antiretroviral therapy in antiretroviral-naive HIV-infected individuals coinfected with hepatitis C" ·
2012
- 2018
Co-PI ·
Merck
· $200,000.00
Randomized controlled trial of efficacy and hepatic safety of raltegravir-based and efavirenz-based antiretroviral therapy in antiretroviral-naive HIV-infected individuals coinfected with hepatitis C
Seed Award in Health Economics of Emerging Infectious Diseases ·
2011
- 2013
PI ·
Li Ka Shing Foundation
· $10,000.00
Health Economics of emerging infectious diseases in Vietnam
International Pilot Award. "Exposure risk factors for HIV-associated Penicillium marneffei infection" ·
2011
- 2013
PI ·
University of Washington Center for AIDS Research
· $10,000.00
Exposure risk factors for Penicillium marneffei infection in HIV infected individuals in Vietnam
Fogarty International Clinical Research Fellowship. "Epidemiology of Penicillium marneffei infection in Vietnam" ·
2009
- 2011
PI ·
NIH
· $135,000.00
Epidemiology of Penicillium marneffei infection in Vietnam
Joint Global Health Trials Award. "A trial of itraconazole versus amphotericin B for initial therapy of HIV-associated penicilliosis" ·
2011
- 2017
PI ·
The Medical Research Council, the Wellcome Trust, and the Department of International Development in the UK
· $2,500,000.00
A randomized controlled trial of itraconazole versus amphotericin B for treatment of HIV-associated talaromycosis (penicilliosis)
Investigator Initiated Clinical Trials Award. "Randomized controlled trial of efficacy and hepatic safety of raltegravir-based and efavirenz-based antiretroviral therapy in antiretroviral-naive HIV-infected individuals coinfected with hepatitis C" ·
2012
- 2018
Co-PI ·
Merck
· $200,000.00
Randomized controlled trial of efficacy and hepatic safety of raltegravir-based and efavirenz-based antiretroviral therapy in antiretroviral-naive HIV-infected individuals coinfected with hepatitis C
Seed Award in Health Economics of Emerging Infectious Diseases ·
2011
- 2013
PI ·
Li Ka Shing Foundation
· $10,000.00
Health Economics of emerging infectious diseases in Vietnam
International Pilot Award. "Exposure risk factors for HIV-associated Penicillium marneffei infection" ·
2011
- 2013
PI ·
University of Washington Center for AIDS Research
· $10,000.00
Exposure risk factors for Penicillium marneffei infection in HIV infected individuals in Vietnam
Fogarty International Clinical Research Fellowship. "Epidemiology of Penicillium marneffei infection in Vietnam" ·
2009
- 2011
PI ·
NIH
· $135,000.00
Epidemiology of Penicillium marneffei infection in Vietnam
Virology Fellow Research Award. "Prevalence and pattern of HIV drug resistance mutations in HIV-01 CRF_AE in Vietnam" ·
2008
- 2010
PI ·
Bristol Myers Squibbs
· $15,000.00
Prevalence and patterns of HIV drug resistance in patients infected with HIV-1 subtype CRF-01AE in Vietnam
T32 Training Grant. "Clinical significance of minority HIV drug resistance mutations using ultra deep sequencing" ·
2007
- 2009
Personal Fellowship ·
NIH
· $120,000.00
Clinical significance of minority HIV drug resistance mutations in patients failing antiretroviral therapy using the 454 ultradeep sequencing technology
Emerging Infectious Disease Laboratory Fellowship. "Molecular epidemiology of Pneumocystis jirovecii infection in the US" ·
1997
- 1999
Personal Fellowship ·
Center for Disease Control and Prevention
· $45,000.00
Molecular epidemiology of Pneumocystis jirovecii clinical isolates and impact on clinical outcomes
Oxford University Clinical Research Unit Internal Grant. "Diagnostic untility of Talaromyces marneffei antigenemia in patients with advanced HIV disease" ·
2018
- 2020
PI ·
Wellcome Trust
· $50,000.00
Faculty Development Award from the Duke Center for AIDS Research ·
2018
- 2020
PI ·
NIH
· $100,000.00
Tackling a neglected HIV-associated infection - A validation study of the IgG and IgM serological responses to talaromycosis ·
August 2020
- July 2021
Duke Center for AIDS Research Pilot Award
· $60,000.00
Development of a point of care diagnostic for the detection of Talaromyces marneffei infection ·
September 2020
- August 2021
NIH SBIR Phase I
· $300,000.00
Early detection of the invasive fungal infection talaromycosis by a novel portable point of care platform ·
March 2020
- February 2021
Duke Global Health Institute
· $25,000.00
Short course liposomal amphotericin B for talaromycosis - a phase II randomized controlled trial ·
February 2021
- January 2024
Gilead Sciences
· $717,000.00
External Relationships
- Gilead Sciences, Inc.
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.